FGF5 and metabolic dysfunction-associated steatohepatitis: Hiromi H et al. (51) discovered that FGF5 was implicated in the progression of liver fibrosis and suggested that FGF5 could potentially serve as a therapeutic target for liver fibrosis in non-alcoholic steatohepatitis.